ACT Stock Overview
Develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
AlzChem Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €57.00 |
| 52 Week High | €64.80 |
| 52 Week Low | €22.20 |
| Beta | 0.96 |
| 1 Month Change | -4.36% |
| 3 Month Change | 29.84% |
| 1 Year Change | 123.53% |
| 3 Year Change | 146.75% |
| 5 Year Change | 168.87% |
| Change since IPO | 111.97% |
Recent News & Updates
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
Nov 14
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27Recent updates
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
Nov 14AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27When Should You Buy AlzChem Group AG (ETR:ACT)?
Oct 18AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
Shareholder Returns
| ACT | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -3.9% | -2.6% |
| 1Y | 123.5% | -8.9% | 6.9% |
Return vs Industry: ACT exceeded the German Chemicals industry which returned -8.9% over the past year.
Return vs Market: ACT exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| ACT volatility | |
|---|---|
| ACT Average Weekly Movement | 6.0% |
| Chemicals Industry Average Movement | 3.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ACT has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ACT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1908 | 1,607 | Andreas Niedermaier | www.alzchem.com |
AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand.
AlzChem Group AG Fundamentals Summary
| ACT fundamental statistics | |
|---|---|
| Market cap | €580.05m |
| Earnings (TTM) | €50.10m |
| Revenue (TTM) | €563.55m |
11.6x
P/E Ratio1.0x
P/S RatioIs ACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACT income statement (TTM) | |
|---|---|
| Revenue | €563.55m |
| Cost of Revenue | €214.74m |
| Gross Profit | €348.81m |
| Other Expenses | €298.71m |
| Earnings | €50.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | 4.92 |
| Gross Margin | 61.90% |
| Net Profit Margin | 8.89% |
| Debt/Equity Ratio | 0% |
How did ACT perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield24%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AlzChem Group AG is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Lopez Pineda | Baader Helvea Equity Research |
| Konstantin Wiechert | Baader Helvea Equity Research |
| Knut Woller | Baader Helvea Equity Research |